Abstract
ABSTRACT: Thirty and forty days after a 50 mg medroxyprogesterone acetate injection, respectively, two mixed-breed, 7 and 8-month-old entire male cats presented diffuse enlargement of thoracic and abdominal mammary glands, with ulceration, abscessation and necrosis. One patient was treated with 10 mg/kg aglepristone, antibiotic therapy, analgesic and non-steroidal anti-inflammatory compound; however a worse enlargement of mammary glands, necrosis and clinical condition was noted two days after antiprogestin injection. The second patient was submitted to surgical procedure without previous medical treatment. A partial bilateral mastectomy and conventional orchiectomy were performed, and both patients presented no clinical abnormalities 10 days after surgical treatment. In the male cat, the interruption of progesterone associated mammary fibroepithelial hyperplasia cannot be based in gonadectomy, being antiprogestin treatment the primary approach. Mastectomy can be a treatment option in selected cases, such as the two cases presented here, in case of antiprogestin treatment failure or in case of extensive ulceration, necrosis and risk of sepsis.
Highlights
Feline mammary fibroepithelial hyperplasia (MFEH) represents a growth disturbance in cats characterized by the rapid and non-neoplastic proliferation of the ductal epithelium and stroma of the mammary gland
MFEH has been described after MPA or megestrol acetate (MA) injection, considering that these drugs are widely used for a variety of reproductive, behavioral, and dermatologic conditions, or after accidental contact with progestin components in the environment (DORN, et al, 1983; GÖRLINGER et al, 2002; HAYDEN, et al, 1989; JELINEK et al, 2007; LEIDINGER et al, 2011; MACDOUGALL, 2003; MAYAYO, et al, 2018; MEISL, et al, 2003; PAYANCARREIRA, 2013; SONTAS et al, 2008)
The purpose of the present study is to report the successful treatment and outcome of two male cats presenting MFEH after the improper use of a single injection of synthetic progestin
Summary
Feline mammary fibroepithelial hyperplasia (MFEH) represents a growth disturbance in cats characterized by the rapid and non-neoplastic proliferation of the ductal epithelium and stroma of the mammary gland. V.51, n.4, 1989), before puberty, a few weeks after estrus, during pregnancy or pseudopregnancy, or due to exogenous synthetic progestins, such as megestrol acetate (MA) and acetate medroxyprogesterone (MPA) injections, commercially available as a depot contraceptive drug for entire female cats (GÖRLINGER et al, 2002; GRIFFIN, 2001; GUDERMUTH et al, 1997; HAYDEN et al, 1981; HAYDEN, et al, 1989; JELINEK et al, 2007; NOAKES et al, 2018). MFEH has been described after MPA or MA injection, considering that these drugs are widely used for a variety of reproductive, behavioral, and dermatologic conditions, or after accidental contact with progestin components in the environment (DORN, et al, 1983; GÖRLINGER et al, 2002; HAYDEN, et al, 1989; JELINEK et al, 2007; LEIDINGER et al, 2011; MACDOUGALL, 2003; MAYAYO, et al, 2018; MEISL, et al, 2003; PAYANCARREIRA, 2013; SONTAS et al, 2008).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
